



PCT/GB 2003 / 0 0 1 7 7 Z



INVESTOR IN PEOPLE

NOT AVAILABLE COPY

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office

Concept House

Cardiff Road 04 JUN 2003

Newport

South Wales

NP10 8QQ

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Andrew Geiseg

Dated

14 May 2003




The Patent Office

1/77

Form for grant of a patent

Fill in on the back of this form. You can also get a copy of the leaflet from the Patent Office to help you fill in this form.



The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Reference

T1576PV

02MAY02 E715492-1 D02639
P01/7700 0.00-0209995.0

Application number
The Patent Office will fill in this part)

0209995.0

01 MAY 2002

Name, address and postcode of the owner or
applicant (underline all surnames)

Merck Sharp & Dohme Limited
Hertford Road, Hoddesdon
Hertfordshire EN11 9BU
United Kingdom

ADP number (if you know it)

00597799001 ✓

If applicant is a corporate body, give the
country of its incorporation

United Kingdom

Nature of the invention

Therapeutic agents

Name of your agent (if you have one)

Mr. J. Horgan

Address for service" in the United Kingdom
To which all correspondence should be sent
(give the postcode)

Merck & Co., Inc.
European Patent Department
Terlings Park
Eastwick Road
Harlow
Essex CM20 2QR

ADP number (if you know it)

07536832001

444879 1001

If you are declaring priority from one or more
previous patent applications, give the country
of first filing of the application and (if you know it) the
application number

Country

Priority Application number
(if you know it)

Date of filing
(day/month/year)

If your application is divided or otherwise
derived from an earlier UK application, give
the number and the filing date of the
earlier application

Number of earlier application

Date of filing
(day/month/year)

Statement of inventorship and of right
to a patent required in support of
the application? (Answer 'Yes' if:

Yes

the applicant named in part 3 is not an inventor, or
the applicant is an inventor who is not named as an
inventor, or
the applicant is a corporate body.
(d))

Patents Form 1/77

or the number of sheets for any of the
following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form	0
Description	32
Claim(s)	0
Abstract	0
Drawing(s)	0

You are also filing any of the following,
show how many against each item.

Priority documents	-
Translations of priority documents	-
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	-
Request for preliminary examination and search (Patents Form 9/77)	-
Request for substantive examination (Patents Form 10/77)	-
Any other documents (please specify)	-

I/We request the grant of a patent on the basis of this application.

Signature

Mr. J. Horgan

Date 01 May 2002

and daytime telephone number of
person to contact in the United Kingdom

Mr. J. Horgan

01279 440625

When an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You are warned if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or such direction has been given, or any such direction has been revoked.

If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

Write your answers in capital letters using black ink or you may type them.

If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.

If you have answered 'Yes' Patents Form 7/77 will need to be filed.

If you have filled in the form you must remember to sign and date it.

For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1/77

THERAPEUTIC AGENTS

The present invention relates to a novel class of compounds, their salts, pharmaceutical compositions comprising them, processes for making them and their use in therapy of the human body. In particular, the invention
5 relates to compounds which modulate the processing of APP by γ -secretase, and hence are useful in the treatment or prevention of Alzheimer's disease.

Alzheimer's disease (AD) is the most prevalent form of dementia. Although primarily a disease of the elderly, affecting up to 10% of the
10 population over the age of 65, AD also affects significant numbers of younger patients with a genetic predisposition. It is a neurodegenerative disorder, clinically characterized by progressive loss of memory and cognitive function, and pathologically characterized by the deposition of extracellular proteinaceous plaques in the cortical and associative brain
15 regions of sufferers. These plaques mainly comprise fibrillar aggregates of β -amyloid peptide ($A\beta$), and although the exact role of the plaques in the onset and progress of AD is not fully understood, it is generally accepted that suppressing or attenuating the secretion of $A\beta$ is a likely means of alleviating or preventing the condition. (See, for example, *ID research*
20 *alert* 1996 1(2):1-7; *ID research alert* 1997 2(1):1-8; *Current Opinion in CPNS Investigational Drugs* 1999 1(3):327-332; and *Chemistry in Britain*, Jan. 2000, 28-31.)

$A\beta$ is a peptide comprising 39-43 amino acid residues, formed by proteolysis of the much larger amyloid precursor protein. The amyloid
25 precursor protein (APP or $A\beta$ PP) has a receptor-like structure with a large ectodomain, a membrane spanning region and a short cytoplasmic tail. Different isoforms of APP result from the alternative splicing of three exons in a single gene and have 695, 751 and 770 amino acids respectively.

The $A\beta$ domain encompasses parts of both extra-cellular and
30 transmembrane domains of APP, thus its release implies the existence of two distinct proteolytic events to generate its NH_2 - and $COOH$ -termini. At

least two secretory mechanisms exist which release APP from the membrane and generate the soluble, COOH-truncated forms of APP (APP_s). Proteases which release APP and its fragments from the membrane are termed "secretases". Most APP_s is released by a putative α-secretase which cleaves within the Aβ domain (between residues Lys¹⁶ and Leu¹⁷) to release α-APP_s and precludes the release of intact Aβ. A minor portion of APP_s is released by a β-secretase, which cleaves near the NH₂-terminus of Aβ and produces COOH-terminal fragments (CTFs) which contain the whole Aβ domain. Finding these fragments in the extracellular compartment suggests that another proteolytic activity (γ-secretase) exists under normal conditions which can generate the COOH-terminus of Aβ.

It is believed that γ-secretase itself depends for its activity on the presence of presenilin-1. In a manner that is not fully understood presenilin-1 appears to undergo autocleavage.


There are relatively few reports in the literature of compounds with inhibitory activity towards β- or γ-secretase, as measured in cell-based assays. These are reviewed in the articles referenced above. Many of the relevant compounds are peptides or peptide derivatives.

WO 01/70677 discloses certain sulphonamido-substituted bridged bicycloalkyl derivatives which are useful in the treatment of Alzheimer's disease, but neither discloses nor suggests the compounds of the present invention.

The present invention provides a novel class of non-peptidic compounds which are useful in the treatment or prevention of AD by modulating the processing of APP by the putative γ-secretase, thus arresting the production of Aβ and preventing the formation of insoluble plaques.

According to the invention there is provided a compound of formula

30 I:



I

wherein the moiety X-R is attached at one of the positions indicated by an asterisk;

X is a bivalent 1,2,4-oxadiazole residue; and

5 R is selected from:

(i) a non-aromatic hydrocarbon-group of up to 10-carbon atoms, optionally substituted with halogen, CF₃, CHF₂, CN, OH, CO₂H, C₂₋₆acyl, C₁₋₄alkoxy or C₁₋₄alkoxycarbonyl;

10 (ii) a non-aromatic heterocyclic group comprising up to 7 ring atoms of which up to 3 are chosen from N, O and S and the remainder are carbon, bearing 0-3 substituents independently selected from oxo, halogen, CN, C₁₋₆alkyl, OH, CF₃, CHF₂, CH₂F, C₂₋₆acyl, CO₂H, C₁₋₄alkoxy and C₁₋₄alkoxycarbonyl; and

15 (iii) phenyl or 6-membered heteroaryl, either of which bears 0-3 substituents independently selected from halogen, CF₃, CHF₂, CH₂F, NO₂, CN, OCF₃, C₁₋₆alkyl and C₁₋₆alkoxy; or a pharmaceutically acceptable salt thereof.

In a preferred embodiment of the invention, R represents a group selected from those set forth under (iii) above.

20 It will be readily apparent to those skilled in the art that the compounds of formula I exist in two enantiomeric forms, depending on which of the ring positions indicated by an asterisk is bonded to the moiety -X-R. It is to be emphasised that the invention, for each identity of -X-R, encompasses both enantiomers, either as homochiral compounds or as
 25 ~~mixtures of enantiomers in any proportion. Furthermore, structural~~
~~formulae depicting attachment of -X-R or a synthetic precursor thereof at~~

one of the said ring positions shall hereinafter be indicative of attachment at either or both of said ring positions, unless expressly stated otherwise.

Where a variable occurs more than once in formula I or in a substituent thereof, the individual occurrences of that variable are
5 independent of each other, unless otherwise specified.

As used herein, the expression "C_{1-x}alkyl" where x is an integer greater than 1 refers to straight-chained and branched alkyl groups wherein the number of constituent carbon atoms is in the range 1 to x. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl and t-butyl.
10 Derived expressions such as "C₂₋₆alkenyl", "hydroxyC₁₋₆alkyl", "heteroarylC₁₋₆alkyl", "C₂₋₆alkynyl" and "C₁₋₆alkoxy" are to be construed in an analogous manner. Most suitably, the number of carbon atoms in such groups is not more than 4.

The expression "C₃₋₆cycloalkyl" as used herein refers to nonaromatic
15 monocyclic hydrocarbon ring systems comprising from 3 to 6 ring atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cyclohexenyl.

The expression "C₃₋₆ cycloalkyl(C₁₋₆)alkyl" as used herein includes cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl and
20 cyclohexylmethyl.

The expression "C₂₋₆acyl" as used herein refers to (C₁₋₅alkyl)carbonyl groups, such as acetyl, propanoyl and butanoyl, including cycloalkyl derivatives such as cyclopentanecarbonyl and cyclobutanecarbonyl, and fluorinated derivatives such as trifluoroacetyl.

25 The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, of which fluorine and chlorine are preferred.

For use in medicine, the compounds of formula I may advantageously be in the form of pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds of

30 formula I or of their pharmaceutically acceptable salts. Suitable
pharmaceutically acceptable salts of the compounds of this invention

include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.

Where the compounds according to the invention have at least one asymmetric centre, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centres, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.

In the compounds of formula I, X is a bivalent 1,2,4-oxadiazole residue. X may be bonded to R and to the fused benzene ring via either of the available ring positions of X. Thus, the fragment -X-R may represent a 5-(R-substituted)-1,2,4-oxadiazol-3-yl moiety or a 3-(R-substituted)-1,2,4-oxadiazol-5-yl moiety.

In one embodiment, R is a non-aromatic hydrocarbon group of up to 10 carbon atoms, optionally substituted with halogen, CF₃, CHF₂, CN, OH, CO₂H, C₂₋₆acyl, C₁₋₄alkoxy or C₁₋₄alkoxycarbonyl. Within this definition, R may comprise cyclic or acyclic hydrocarbon residues or combinations thereof, saturated or unsaturated, up to a maximum of 10 carbon atoms in total, and may bear a substituent as detailed above. Within this embodiment, R typically contains up to 6 carbon atoms. Suitable examples include alkyl groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, t-butyl and 2-methylpropyl, cycloalkyl groups such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, cycloalkylalkyl groups

such as cyclopropylmethyl and cyclopentylmethyl, alkenyl groups such as allyl, cyclopentenyl and cyclohexenyl, and alkynyl groups such as propargyl.













In a second embodiment, R represents a non-aromatic heterocyclic group comprising up to 7 ring atoms of which up to 3 are chosen from N, O and S and the remainder are carbon, bearing 0-3 substituents independently selected from oxo, halogen, CN, C₁₋₆alkyl, OH, CF₃, CHF₂, CH₂F, C₂₋₆acyl, CO₂H, C₁₋₄alkoxy and C₁₋₄alkoxycarbonyl. Suitable heterocyclic groups include pyrrolidine, piperidine, tetrahydropyridine, piperazine, morpholine, thiomorpholine, thiomorpholine-1,1-dioxide, pyran and thiopyran. Heterocyclic groups containing one or more nitrogen atoms may be bonded to X via carbon or via nitrogen. Within this embodiment, R very aptly represents 1-acetylpiperidin-4-yl.

In a third embodiment, R represents phenyl or 6-membered heteroaryl, either of which bears 0-3 substituents independently selected from halogen, CF₃, CHF₂, CH₂F, NO₂, CN, OCF₃, C₁₋₆alkyl and C₁₋₆alkoxy. Examples of suitable 6-membered heteroaryl groups represented by X include pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl and triazinyl. Preferably, the phenyl or heteroaryl ring bears 0 to 2 substituents. Phenyl groups represented by R preferably bear at least one substituent. Preferred substituents include halogen (especially chlorine and fluorine) and CF₃. Within this embodiment, examples of groups represented by R include monohalophenyl, dihalophenyl, pyridyl, monohalopyridyl and trifluoromethylpyridyl, wherein "halo" refers to fluoro or chloro. Suitable specific values for R include 2-fluorophenyl, 2-chlorophenyl, 4-fluorophenyl, 4-chlorophenyl, 2,4-difluorophenyl, 2,4-dichlorophenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrazin-2-yl, 5-fluoropyridin-2-yl, 5-chloropyridin-2-yl, 5-(trifluoromethyl)pyridin-2-yl and 6-(trifluoromethyl)pyridin-3-yl, and preferred examples include 4-


fluorophenyl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrazin-2-yl, 5-

fluoropyridin-2-yl, 5-chloropyridin-2-yl, 5-(trifluoromethyl)pyridin-2-yl, and 6-(trifluoromethyl)pyridin-3-yl.

Representative compounds in accordance with the invention include those in which the moiety -X-R is selected from:



and



The compounds of the present invention have an activity as inhibitors of γ secretase.

The invention also provides pharmaceutical compositions comprising one or more compounds of this invention and a pharmaceutically acceptable carrier. Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid

sprays, drops, ampoules, transdermal patches, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums or surfactants such as sorbitan monooleate, polyethylene glycol, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Typical unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of the active ingredient. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

The present invention also provides a compound of the invention or a pharmaceutically acceptable salt thereof for use in a method of treatment of the human body. Preferably the treatment is for a condition associated with the deposition of β -amyloid. Preferably the condition is a neurological disease having associated β -amyloid deposition such as Alzheimer's disease.

The present invention further provides the use of a compound of the present invention or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing Alzheimer's disease.


Also disclosed is a method of treatment of a subject suffering from or prone to Alzheimer's disease which comprises administering to that subject an effective amount of a compound according to the present invention or a pharmaceutically acceptable salt thereof.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, poly(vinylpyrrolidone) or gelatin.

For treating or preventing Alzheimer's Disease, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.01 to 100 mg/kg per day, and especially about 0.01 to 50 mg/kg of body weight per day. The compounds may be administered on a regimen of 1 to 4 times per day. In some cases, however, a dosage outside these limits may be used.


The compounds of the invention are particularly suitable for oral administration.

Suitable starting materials for the preparation of the compounds of formula I are the ketones II:



II


wherein Y represents alkoxycarbonyl (especially CO₂Me or CO₂Et) or benzyloxy. Treatment of the ketones II with t-butylsulphonamide in the presence of TiCl₄ and triethylamine in refluxing dichloroethane provides the sulphonylimines III(a):



III (a) n = 2
(b) n = 1

where Y has the same meaning as before. Alternatively, treatment of the ketones II with t-butylsulphinamide in the presence of Ti(OEt)₄ in refluxing tetrahydrofuran provides the sulphinylimines III(b).


Both types of imine III react with trimethylsulphoxonium iodide to provide aziridines IV:



IV (a) n = 2
(b) n = 1

where Y has the same meaning as before. The reaction takes place in the presence of sodium hydride at ambient temperature in a THF-DMSO mixture or at 0°C in DMSO.

Reaction of sulphonamides IV(a) with CF₃CH₂NH₂, followed by cleavage of the t-butylsulphonyl group, provides diamines V:




V

where Y has the same meaning as before. Ring-opening of the aziridine is typically effected by heating with $\text{CF}_3\text{CH}_2\text{NH}_2$ at 100°C in DMF or DMSO in a sealed tube, while cleavage of the t-butylsulphonyl group may be effected by treatment with trifluoromethanesulphonic acid at 0°C .

Alternatively, the diamines V may be formed directly by reaction of the sulphinamides IV(b) with $\text{CF}_3\text{CH}_2\text{NH}_2$ in the presence of zinc iodide in dichloroethane at 100°C .

Reaction of diamines V with sulphamide ($\text{H}_2\text{NSO}_2\text{NH}_2$) in refluxing anhydrous pyridine provides the cyclic sulphamides VI(a) and (b):




(a) Y = alkoxycarbonyl

(b) Y = benzyloxy

VI


Compounds VI(a) and (b) are key intermediates for the preparation of compounds of formula I since the substituent Y may be transformed into the moiety $-\text{X}-\text{R}$ by various standard synthetic techniques.

Hydrolysis of the esters VI(a) (for example, using sodium hydroxide in aqueous THF at 60°C) provides the acid VII which serves as the precursor for suitable heteroaryl structures.



VII


In one process, the acid VII is reacted with a carboxamidoxime $R-C(=NOH)NH_2$ to provide a 1,2,4-oxadiazol-5-yl derivative VIII:



VIII

where R has the same meaning as before. The process involves an initial
5 coupling (e.g. using carbonyldiimidazole in DMF at 70°C) followed by
treatment with strong base (e.g. potassium t-butoxide in THF at room
temperature).


The acid VII alternatively may be converted to the corresponding
nitrile IX, which also serves as precursor for heteroaryl derivatives in
10 accordance with formula I.



IX

The nitrile is readily formed by first converting the acid to the
corresponding carboxamide, then reacting it with triflic anhydride in the
presence of triethylamine in dichloromethane at ambient temperature.
15 The amide may be formed by treatment of the acid firstly with
pentafluorophenol and dicyclohexylcarbodiimide, and then with ammonia.


The nitrile IX may be converted to the corresponding amidoxime by
treatment with hydroxylamine hydrochloride in refluxing ethanolic
sodium hydroxide solution. Subsequent coupling with a carboxylic acid
20 RCO_2H and cyclisation provides a 1,2,4-oxadiazol-3-yl derivative X:



X

where R has the same meaning as before. The coupling may be carried out using carbonyldiimidazole in DMF at 70°C, while the final cyclisation may be effected by treatment with toluenesulphonic acid in a refluxing DMF-toluene mixture.


The benzyl ether VI(b) may be converted to the corresponding phenol by hydrogenation over Pd/C, and thence to the triflate XI by treatment with triflic anhydride in the presence of pyridine in dichloromethane at 0°C:



XI

where Tf represents triflyl (i.e. trifluoromethanesulphonyl). The triflate XI is another precursor of compounds in accordance with formula I.

Thus, XI may be converted to a boronic acid derivative XII:



XII

where R² represents H or alkyl, or the two OR² groups complete a cyclic boronate ester such as the pinacolate. The conversion may be achieved by conventional means using a suitable boron reagent, such as bis(pinacolato)diboron, in the presence of a Pd(II) catalyst such as

bis(diphenylphosphinoferrocene)dichloropalladium(II), typically in the presence of potassium acetate in DMF at 100°C.

Reaction of boronates XII with R-X-L, where L is a suitable leaving group (such as halogen, especially bromine or iodine) and R and X have the same meanings as before, provides compounds of formula I directly. The reaction takes place in the presence of the same Pd catalyst as used in the preparation of XII.

Alternatively, the R-X moiety may be assembled in a three-stage process in which firstly an HX- group is introduced by reaction of boronate XII with HX-L, where L and X have the same meanings as before; secondly, the resulting product is brominated to convert the HX- group to Br-X-; and thirdly, reaction with R-B(OR²) provides a compound of formula I, where R and R² have the same meanings as before.

It will be apparent to those skilled in the art that, in many cases, the steps in the synthetic schemes described above may be carried out in a different order. Thus, if desired, the group Y in ketones II may be converted to the moiety R-X- by one of the described routes prior to the construction of the spiro-linked sulphamide ring.

It will also be appreciated that where more than one isomer can be obtained from a reaction then the resulting mixture of isomers can be separated by conventional means.

Where the above-described process for the preparation of the compounds according to the invention gives rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The novel compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The novel compounds may, for example, be resolved into their component enantiomers by standard techniques such as preparative HPLC, or the formation of

diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid,

followed by fractional crystallization and regeneration of the free base. The novel compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.

5 In a preferred route to enantiomerically pure compounds of formula I, racemic intermediates VI(a) or VI(b) are subjected to preparative chiral HPLC to provide the corresponding homochiral intermediates, which are then converted to homochiral compounds of formula I by the routes indicated above.

10 Where they are not commercially available, the starting materials and reagents used in the above-described synthetic schemes may be prepared by conventional means. The ketones II may be prepared by the method described in *J.Org.Chem.*, 47, 4329-34, 1987.

During any of the above synthetic sequences it may be necessary
15 and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in *Protective Groups in Organic Chemistry*, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, *Protective Groups in Organic Synthesis*, John Wiley & Sons,
20 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

A typical assay which can be used to determine the level of activity of compounds of the present invention is as follows:

(1) Mouse neuroblastoma neuro 2a cells expressing human app695 are
25 cultured at 50-70% confluency in the presence of sterile 10mM sodium butyrate.

(2) Cells are placed in 96-well plates at 30,000/well/100µL in minimal essential medium (MEM) (phenol red-free) + 10% foetal bovine serum (FBS), 50mM HEPES buffer (pH7.3), 1% glutamine, 0.2mg/ml G418

30 antibiotic, 10mM sodium butyrate.

- (3) Make dilutions of the compound plate. Dilute stock solution to 5.5% DMSO/110 μ M compound. Mix compounds vigorously and store at 4°C until use.
- (4) Add 10 μ L compound/well. Mix plate briefly, and leave for 18h in 37°C incubator.
- (5) Remove 90 μ L of culture supernatant and dilute 1:1 with ice-cold 25mM HEPES (pH.3), 0.1% BSA, 1.0mM EDTA (+ broad spectrum protease inhibitor cocktail; pre-aliquotted into a 96-well plate). Mix and keep on ice or freeze at -80°C.
- (6) Add back 100 μ L of warm MEM + 10% FBS, 50mM HEPES (pH7.3), 1% glutamine, 0.2mg/ml G418, 10mM sodium butyrate to each well, and return plate to 37°C incubator.
- (7) Prepare reagents necessary to determine amyloid peptide levels, for example by ELISA assay.
- (8) To determine if compounds are cytotoxic, cell viability following compound administration is assessed by the use of redox dye reduction. A typical example is a combination of redox dye MTS (Promega) and the electron coupling reagent PES. This mixture is made up according to the manufacturer's instructions and left at room temperature.
- (9) Quantitate amyloid beta 40 and 42 peptides using an appropriate volume of diluted culture medium by standard ELISA techniques.
- (10) Add 15 μ L/well MTS/PES solution to the cells; mix and leave at 37°C.
- (11) Read plate when the absorbance values are approximately 1.0 (mix briefly before reading to disperse the reduced formazan product).

Alternative assays are described in *Biochemistry*, 2000, 39(30), 8698-8704.

The compounds of the present invention show unexpectedly high affinities as measured by the above assays. Thus the following Examples

all had an ED₅₀ of less than 50nM, typically less than 10nM, and frequently about 1nM in at least one of the above assays. In general, the

compounds also exhibit good oral bioavailability and/or brain penetration, and are largely free from undesirable biological interactions with potential to cause toxic side effects.

The following examples illustrate the present invention.


5

EXAMPLES


Intermediate A

[6S/R,9R/S,11R/S] 2',3',4',5,5',6,7,8,9,10-Decahydro-2-carboxy-5'-(2,2,2-trifluoroethyl)-spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide

10



Step 1: Methyl 11-Oxo-5,6,7,8,9,10-hexahydro-6,9-methanobenzocyclooctene-2-carboxylate




15

Prepared using the procedure described for 11-oxo-5,6,7,8,9,10-hexahydro-6,9-methanobenzocyclooctene (Justus Liebigs Ann. Chem. 1961, 650, 115) using methyl 3,4-bis(bromomethyl)benzoate in place of 1,2-bis(bromomethyl)benzene.

20

Step 2: Methyl 11-(2'-Methyl-propane-2'-sulfonylimino)-5,6,7,8,9,10-hexahydro-6,9-methanobenzocyclooctene-2-carboxylate




A solution of titanium (IV) chloride (25 mL, 1M in DCM) was added at r.t. to a stirred suspension of the ketone from Step 1 (10.0 g), *tert*-butyl

25

sulfonamide (5.8 g) and triethylamine (11.6 mL) in 1,2-dichloroethane (100 mL). The yellow suspension was stirred under nitrogen for 30 minutes,

then refluxed for 8 hours. The mixture was diluted with dichloromethane (400 mL) and saturated aqueous sodium hydrogencarbonate (400 mL) and filtered through a pad of Celite. The organic phase was dried (Na_2SO_4), filtered and concentrated to give the sulfonimine (15.5 g, quantitative) as a brown gum. δ (^1H , 360MHz, CDCl_3) 1.20-1.40 (2H, m), 1.50 (9H, s), 1.75-2.00 (2H, m), 2.90-2.95 (2H, m), 3.05-3.20 (3H, m), 3.92 (3H, s), 3.95-4.05 (1H, m), 7.24-7.28 (1H, m), 7.84-7.87 (2H, m).


Step 3: Methyl [6S/R,9R/S,11R/S]-11-[(2'-Methyl-propane-2'-sulfonyl)-1'-aza-spiro[2.4]]-5,6,7,8,9,10-hexahydro-6,9-methanobenzocyclooctene-2-carboxylate



Sodium hydride (55%, 1.75 g) was added portionwise at room temperature to a stirred suspension of trimethylsulfoxonium iodide (8.8 g) in DMSO (70 mL) under nitrogen. After stirring for 2 hours, the solution was cooled in an ice-bath and a solution of the sulfonimine from Step 2 (10.0 g) in DMSO (80 mL) was added. The mixture was stirred at room temperature for 2.5 hours then poured onto ice (500 mL) and diluted with water (200 mL).


The white solids were collected, rinsed with diethyl ether and dried under vacuum at room temperature to give the aziridine (8.16 g, 79%). MS (ES+) 400 ($[\text{MNa}]^+$).

Step 4: Methyl [6S/R,9R/S,11R/S]-11-(2'-Methyl-propane-2'-sulfonylamino)-11-(2,2,2-trifluoroethyl)aminomethyl-5,6,7,8,9,10-hexahydro-6,9-methanobenzocyclooctene-2-carboxylate




A solution of the aziridine from Step 3 (8.16 g) and 2,2,2-trifluoroethylamine (10.2 mL) in DMSO (45 mL) was divided into 3 equal portions and stirred at 100°C in sealed tubes for 6 days. The cooled solutions were combined and poured into water (250 mL). The white crystalline solid was collected, rinsed with diethyl ether and dried under vacuum at room temperature to give the amine (7.43 g, 72%). MS (ES+) 477 ([MH]⁺).

Step 5: Methyl [6S/R,9R/S,11R/S] 11-Amino-11-(2,2,2-trifluoroethyl)aminomethyl-5,6,7,8,9,10-hexahydro-6,9-methanobenzocyclooctene-2-carboxylate




Trifluoromethanesulfonic acid (11 mL) was added dropwise at 0°C to a stirred suspension of the sulfonamide from Step 4 (7.43 g) in dichloromethane (100 mL) under nitrogen. The mixture was stirred at 0°C for 20 minutes, then at room temperature for 4 hours. The mixture was poured into saturated aqueous sodium hydrogencarbonate (600 mL) and extracted with 10% methanol-dichloromethane (2x 300 mL). The extracts were washed with brine (100 mL), dried over Na₂SO₄, filtered and concentrated to give the diamine (6.5 g, quantitative) as a yellow oil. MS (ES+) 357 ([MH]⁺).

Step 6: [6S/R,9R/S,11R/S] 2',3',4',5,5',6,7,8,9,10-Decahydro-2-carbomethoxy-5'-(2,2,2-trifluoroethyl)-spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide



A solution of the diamine from Step 5 (6.5 g) and sulfamide (4.5 g) was relaxed in pyridine (120 mL) for 6 hours. Solvent was removed by evaporation. The residue was partitioned between 1M HCl (200 mL) and 10% methanol-dichloromethane (500 mL). The organic extract was washed with brine (100 mL), dried over Na₂SO₄, filtered and concentrated. The solid was rinsed with diethyl ether to give the cyclic sulfamide (5.26 g, 80%) as an off-white powder. δ (¹H, 360MHz, CDCl₃) 1.26-1.30 (2H, m), 1.70-1.75 (2H, m), 2.47-2.50 (2H, m), 2.74-2.82 (2H, m), 3.21-3.29 (2H, m), 3.41-3.47 (2H, m), 3.68 (2H, q, *J*=9), 3.90 (3H, s), 4.78 (1H, s), 7.17 (1H, d, *J*=8), 7.78-7.80 (2H, m)


Step 7: [6S/R,9R/S,11R/S] 2',3',4',5',5',6,7,8,9,10-Decahydro-2-carboxy-5'-(2,2,2-trifluoroethyl)-spiro[6.9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide



A mixture of 4M sodium hydroxide (3 mL) and the ester from Step 6 (2.33 g) in tetrahydrofuran (30 mL) was stirred at 60°C for 3.5 hours. The mixture was diluted with 1M citric acid (10 mL) and 1M hydrochloric acid (20 mL) and extracted with dichloromethane (2 x 100 mL). The extracts were washed with water (100 mL), brine (100 mL), dried over Na₂SO₄, filtered and concentrated. Trituration with diethyl ether – isohexane gave the acid (1.96 g, 88%) as an off-white solid. δ (¹H, 360MHz, d₆-DMSO) 0.95-1.05 (2H, m), 1.65-1.75 (2H, m), 2.35-2.42 (2H, m), 2.62-2.72 (2H, m), 3.18-3.23 (2H, m), 3.47 (2H, s), 4.02 (2H, q, *J*=10), 7.23 (1H, d, *J*=8), 7.62-7.70 (2H, m), 8.03 (1H, s), 12.60 (1H, s).


Example 1

[6S/R,9R/S,11R/S]-2',3',4',5,5',6,7,8,9,10-Decahydro-2-(5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl)-5'-(2,2,2-trifluoroethyl)spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide



5

Step 1 : [6S/R,9R/S,11R/S]-2',3',4',5,5',6,7,8,9,10-Decahydro-2-amidoxime-5'-(2,2,2-trifluoroethyl)spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide



- 10 Pentafluorophenol (0.341 g, 1.85 mmol) and *N,N'*-dicyclohexylcarbodiimide (0.382 g, 1.85 mmol) were added to a suspension of Intermediate A (0.5 g, 1.24 mmol) in ethyl acetate (30 mL) and the reaction was stirred at room temperature for 1 hour after which time it was homogeneous. The solvent was removed *in vacuo*. Ethyl acetate was added to the residue and the
- 15 resulting white solid removed by filtration. The filtrate was evaporated *in vacuo*. The residue was dissolved in dichloromethane (50 mL) and ammonia gas was bubbled through until the mixture was cloudy. The reaction was stirred for 1 hour at room temperature. The solvent was removed *in vacuo* and the residue purified by flash column
- 20 chromatography on silica, eluting with 20% ethyl acetate – isohexane followed by 5% methanol – dichloromethane, to give the carboxamide (0.385 g, 77%).

A solution of this (0.2 g, 0.5 mmol) and


(methoxycarbonylsulfamoyl)triethyl-ammonium hydroxide, inner salt,

- 25 (0.177 g, 1.74 mmol) in tetrahydrofuran (10 mL) was heated under reflux

for 4 hours. The solvent was removed *in vacuo* and the residue purified by flash column chromatography on silica, eluting with 25% ethyl acetate – isohexane, to give the nitrile (0.115 g, 60%).

A solution of this (0.1 g, 0.26 mmol), hydroxylamine hydrochloride (0.027 g, 0.39 mmol) and triethylamine (65 μ L, 0.47 mmol) in ethanol (5 mL) was heated under reflux for 18 hours. The cooled reaction mixture was poured into sodium hydroxide solution (1M aq; 25 mL) and extracted with ethyl acetate (25 mL). The organic layer was washed with water (25 mL) and brine (25 mL), dried over Na_2SO_4 and evaporated to give the amidoxime (0.038 g, 35%). MS (ES+) 419, 420, 421.

Step 2 : [6S/R,9R/S,11R/S]-2',3',4',5,5',6,7,8,9,10-Decahydro-2-(5-(4-fluorophenyl)-1,2,4-oxadiazol-3-yl)-5'-(2,2,2-trifluoroethyl)spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide



15


1,1'-Carbonyldiimidazole (0.032 g, 0.2 mmol) was added to a solution of 4-fluorobenzoic acid (0.028 g, 0.2 mmol) in *N,N*-dimethylformamide (3 mL) under nitrogen and stirred at room temperature for 1 hour. A solution of amidoxime (0.092 g, 0.22 mmol) in *N,N*-dimethylformamide (3 mL) was added and the reaction stirred at room temperature for 4 hours then at 70°C for 5 hours. The cooled reaction mixture was diluted with ethyl acetate (25 mL) and washed with water (4 x 25 mL) and brine (25 mL), dried over Na_2SO_4 and evaporated. The residue (0.109 g) was dissolved in toluene (5 mL) and *N,N*-dimethylformamide (1 mL). *p*-Toluenesulphonic acid (3 mg) was added and the reaction heated under reflux for 5 hours. The cooled reaction mixture was poured into water (25 mL) and extracted with ethyl acetate (2 x 25 mL). The combined organic layers were washed with brine (25 mL), dried over Na_2SO_4 and evaporated. The residue was

purified by flash column chromatography on silica, eluting with 25% ethyl acetate – isohexane to give the title compound (0.055 g, 48%).

δ (^1H , 400MHz, d_4 -MeOH) 1.22-1.30 (2H, m), 1.78-1.81 (2H, m), 2.48-2.53 (2H, m), 2.73-2.82 (2H, m), 3.39 (2H, dd, $J=5, 16$), 3.52 (2H, s), 3.88 (2H, q, $J=9$), 7.29 (1H, d, $J=7.8$), 7.34-7.40 (2H, m), 7.86-7.89 (2H, m), 8.26-8.30 (2H, m); MS (ES+) 523, 524, 526 ($[\text{MH}]^+$).

Example 2

[6S/R,9R/S,11R/S] 2',3',4',5,5',6,7,8,9,10-Decahydro-2-(5-(2-pyridyl)-1,2,4-oxadiazol-3-yl)-5'-(2,2,2-trifluoroethyl)spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide




Prepared in the same way as Example 1 using 0.090 g of amidoxime from Step 1 and picolinic acid (0.024 g, 0.19 mmol) to give the title compound (0.046 g, 41%).

MS (ES+) 506, 507, 508.

Example 3

[6S,9R,11R] 2',3',4',5,5',6,7,8,9,10-Decahydro-2-(5-(pyridin-2-yl)-1,2,4-oxadiazol-3-yl)-5'-(2,2,2-trifluoroethyl)spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide




The racemic oxadiazole Example 2 was resolved by supercritical fluid chromatographic separation on a Chiralcel OD column using 30%

methanol - sc-CO₂ as eluant (50 mL/min) at 35°C, 100 bar and UV detection at 250 nm, collecting the second compound eluted under these conditions.

5 Example 4

[6S/R,9R/S,11R/S]-2',3',4',5,5',6,7,8,9,10-Decahydro-2-(5-(3-pyridyl)-1,2,4-oxadiazol-3-yl)-5'-(2,2,2-trifluoroethyl)spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide




Prepared in the same way as Example 1 using 0.14 g of amidoxime from step 1 and nicotinic acid (0.037 g, 0.3 mmol) to give the title compound (0.027 g, 16%).

MS (ES+) 506, 507, 508, 547, 548

Example 5

[6S/R,9R/S,11R/S] 2',3',4',5,5',6,7,8,9,10-Decahydro-2-(3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)-5'-(2,2,2-trifluoroethyl)spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide




1,1'-Carbonyldiimidazole (0.032 g, 0.2 mmol) was added to a solution of Intermediate A (0.12 g, 0.3 mmol) in *N,N*-dimethylformamide (3 mL) under nitrogen and stirred at room temperature for 1 hour. A solution of 4-fluorobenzamidoxime (0.05 g, 0.33 mmol) in *N,N*-dimethylformamide (3 mL) was added and the reaction stirred at room temperature for 18 hours

then at 50°C for 5 hours then at 70°C for 18 hours. The cooled reaction mixture was diluted with ethyl acetate (25 mL) and washed with water (4 x 25 mL) and brine (25 mL), dried over Na₂SO₄ and evaporated. The residue (0.154 g) was dissolved in tetrahydrofuran (10 mL). Potassium *tert*-butoxide (1.0 M in THF; 0.9 mL, 0.9 mmol) was added and the reaction stirred at room temperature for 66 hours. The mixture was poured into water (25 mL) and extracted with ethyl acetate (2 x 25 mL). The combined organic layers were washed with brine (25 mL), dried over Na₂SO₄ and evaporated. The residue was purified by flash column chromatography on silica twice, eluting with 25% ethyl acetate – isohexane then 20% ethyl acetate – isohexane, followed by preparative HPLC to give the title compound (0.0523g, 15%).

δ (¹H, 400MHz, CDCl₃) 1.32-1.37 (2H, m), 1.73-1.83 (2H, m), 2.50-2.55 (2H, m), 2.84-2.91 (2H, m), 3.28-3.35 (2H, m), 3.46 (2H, s), 3.70 (2H, q, J=8.6), 4.72 (1H, s), 7.20 (2H, t, J=8.6), 7.30 (1H, d, J=8), 7.96-7.97 (2H, m), 8.16-8.19 (2H, m).

Example 6


[6S/R,9R/S,11R/S] 2',3',4',5,5',6,7,8,9,10-Decahydro-2-(3-(2-pyridyl)-1,2,4-oxadiazol-5-yl)-5'-trifluoroethyl-spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide



The title compound was prepared by the method described in Example 5, starting from Intermediate A and pyridyl-2-amidoxime. MS (ES⁺) 506 ([MH]⁺).

Example 7

(-)-[6S,9R,11R] 2',3',4',5,5',6,7,8,9,10-Decahydro-2-(3-(2-pyridyl)-1,2,4-oxadiazol-5-yl)-5'-trifluoroethyl-spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide



5


The title compound was prepared by the method described in Example 5, starting from Intermediate A and pyridyl-2-amidoxime. Chiral SFC semi-preparative separation of enantiomers was carried out using a Chiracel OD column and the following conditions: 20% MeOH/CO₂; 50 mL/min; 35C, 220 nm. The title compound was the first eluted enantiomer. MS (ES⁺) 506 ([MH]⁺); [α]_D -22 (c=0.51, DMSO, 23°C).

10

Example 8

[6S/R,9R/S,11R/S] 2',3',4',5,5',6,7,8,9,10-Decahydro-2-(3-(3-pyridyl)-1,2,4-oxadiazol-5-yl)-5'-(2,2,2-trifluoroethyl)spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide

15



Prepared in the same way as Example 5 using 0.14 g of the acid,

Intermediate A, and 3-pyridylamidoxime (0.056 g, 0.41 mmol) to give the title compound (0.01 g, 6%).


20

MS (ES⁺) 506, 507, 508, 547.

Example 9

[6S/R,9R/S,11R/S] 2',3',4',5,5',6,7,8,9,10-Decahydro-2-(3-(4-pyridyl)-1,2,4-oxadiazol-5-yl)-5'-(2,2,2-trifluoroethyl)spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide

5




Prepared in the same way as Example 5 using 0.14 g of acid Intermediate A and 4-pyridylamidoxime (0.056 g, 0.41 mmol) to give the title compound (0.023 g, 13%).

10 MS (ES+) 506, 507, 508.

Example 10

[6S/R,9R/S,11R/S] 2',3',4',5,5',6,7,8,9,10-Decahydro-2-(3-(5-fluoropyrid-2-yl)-1,2,4-oxadiazol-5-yl)-5'-trifluoroethyl-spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide

15




The title compound was prepared by the method described in Example 5, starting from Intermediate A. The required 5-fluoropyrid-2-ylamidoxime was prepared as described in WO 01/12627 A1. MS (ES+) 524 ([MH]⁺).

20

Example 11

[6S/R,9R/S,11R/S] 2',3',4',5,5',6,7,8,9,10-Decahydro-2-(3-(5-chloro-pyrid-2-yl)-1,2,4-oxadiazol-5-yl)-5'-trifluoroethyl-spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide




5

The title compound was prepared by the method described in Example 5, starting from Intermediate A. The required 5-chloropyrid-2-ylamidoxime was prepared as described in WO 01/12627 A1. MS (ES+) 540 ([MH]⁺).

Example 12

[6S/R,9R/S,11R/S] 2',3',4',5,5',6,7,8,9,10-Decahydro-2-(3-(5-trifluoromethyl-pyridin-2-yl)-1,2,4-oxadiazol-5-yl)-5'-(2,2,2-trifluoroethyl)-spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide



15


Prepared by the method of Example 5 using 5-trifluoromethylpyrid-2-ylamidoxime.

MS (ES+) 574 ([MH]⁺).

20

Example 13

[6S/R,9R/S,11R/S] 2',3',4',5,5',6,7,8,9,10-Decahydro-2-(3-(2-trifluoromethyl-pyridin-5-yl)-1,2,4-oxadiazol-5-yl)-5'-(2,2,2-trifluoroethyl)-spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide




Prepared by the method of Example 5 using 2-trifluoromethylpyrid-5-ylamidoxime.

MS (ES+) 574 ([MH]⁺).


Example 14

[6S,9R,11R] 2',3',4',5,5',6,7,8,9,10-Decahydro-2-(3-(5-trifluoromethyl-pyridin-2-yl)-1,2,4-oxadiazol-5-yl)-5'-(2,2,2-trifluoroethyl)-spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide



The racemic oxadiazole from Example 12 was resolved by supercritical fluid chromatographic separation on a Chiralcel OD column using 30% methanol - sc-CO₂ as eluant (50 mL/min) at 35°C, 100 bar and UV detection at 250 nm, collecting the first compound eluted under these conditions.

Example 15 [6S/R,9R/S,11R/S] 2',3',4',5,5',6,7,8,9,10-decahydro-2-(3-(2-pyrazinyl)-[1,2,4]oxadiazol-5-yl)-5'-(2,2,2-trifluoroethyl)-spiro[6,9-methanobenzocyclooctene-11,3'-[1,2,5]thiadiazole] 1',1'-dioxide




To a stirred solution of Intermediate A (223 mg, 0.55 mmol) in DMF (5 ml) under nitrogen was added 1,1'-carbonyl diimidazole (98 mg, 0.60 mmol). After 1 h, pyrazine-2-carboxamide oxime (84 mg, 0.61 mmol) was added and the resulting solution stirred for 16 h. Analysis by mass spectrometry indicated incomplete reaction. Additional amide oxime (31 mg, 0.22 mmol) was added to the reaction mixture which was then heated at 50°C for 3.5 h. A further portion of amide oxime (38 mg, 0.28 mmol) was added and the mixture heated at 60°C for 3 h. The mixture was allowed to cool and was then partitioned between water and ethyl acetate. The layers were separated and the aqueous phase extracted a second time with ethyl acetate. The combined organic extracts were washed with brine, dried (MgSO₄) and concentrated *in vacuo* to give the acylated amide oxime (265 mg). MS (ES⁺) 525 ([M + H]⁺).

To this product (261 mg, 0.50 mmol) in THF (7 ml) under nitrogen was added potassium *tert*-butoxide solution (1.5 ml of a 1.0 M solution in THF, 1.5 mmol). The resulting suspension was stirred for 15 h at ambient temperature. The mixture was partitioned between dilute aqueous ammonium chloride solution and ethyl acetate. The layers were separated and the aqueous phase extracted a second time with ethyl acetate. The combined organic extracts were washed with brine, dried (MgSO₄) and concentrated *in vacuo*. Trituration with EtOAc/Et₂O afforded the title compound (117 mg). ¹H NMR (400MHz, CDCl₃) δ_H 1.32-1.36 (2H, m), 1.76-1.80 (2H, m), 2.52-2.55 (2H, m), 2.85 (2H, app. dt, *J* = 16.6, 7.8 Hz), 3.29-

3.36 (2H, m), 3.44-3.47 (2H, m), 3.68 (1H, d, $J = 8.7$ Hz), 3.73 (1H, d, $J = 8.7$ Hz), 4.83 (1H, s), 7.32 (1H, d, $J = 7.8$ Hz), 8.03 (1H, dd, $J = 7.8, 1.5$ Hz), 8.07 (1H, s), 8.76 (1H, br s), 8.80-8.81 (1H, m), 9.46 (1H, br s); MS (ES+) 507[M + H]⁺.

5

Example 116. [6S/R,9R/S,11R/S] 2',3',4',5,5',6,7,8,9,10-decahydro-2-(3-(1-acetylpiperidin-4-yl)-[1,2,4]oxadiazol-5-yl)-5'-(2,2,2-trifluoroethyl)-spiro[6,9-methanobenzocyclooctene -11,3'-[1,2,5]thiadiazole] 1',1'-dioxide



10

Step 1: 1-acetylpiperidine-4-carboxamidoxime.

1-Acetylpiperidine-4-carbonitrile (300 mg, 1.96 mmol), hydroxylamine hydrochloride (204 mg, 2.94 mmol) and triethylamine (492 μ l, 3.53 mmol) were combined in ethanol (10 ml) and heated under reflux overnight. The solvent was removed *in vacuo*, and the residue triturated with ethanol to give the amidoxime as its hydrochloride salt (100 mg, 23%).

15

m/z 186, 187.

Step 2:

N,N'-carbonyldiimidazole (53 mg, 0.33 mmol) was added to a solution of Intermediate A (120 mg, 0.30 mmol) in DMF (3 mL) and stirred at room temperature for one hour. A sonicated mixture of amidoxime hydrochloride from step 1 (73 mg, 0.33 mmol) and Hünig's base (114 μ l, 0.66 mmol) in DMF (3 mL) was added and the reaction stirred at 70°C overnight. The cooled reaction mixture was diluted with ethyl acetate (25 mL), washed with water (4 x 25 mL) and brine (25 mL) and dried (Na₂SO₄). The solvent was removed *in vacuo*. The residue (95 mg) was dissolved in THF (10 mL) and potassium *tert*-butoxide (1.0 M in THF; 0.5 mL, 0.5 mmol) was added.

20

25

After stirring at room temperature for 65 hours, the mixture was poured

into water (25 mL) and extracted with ethyl acetate (2 x 25 mL). The combined organic layers were washed with brine (25 mL), dried (Na_2SO_4) and evaporated under reduced pressure. The residue was purified by FractionLynx, after flash column chromatography and preparative TLC
5 failed to remove impurities, to give the title cyclic sulfamide (6 mg, 4% over 2 steps).

δ (^1H , 360MHz, CDCl_3) 7.87-7.86 (2H, m), 7.27 (1H, d, $J=8.6$), 4.82 (1H, s), 4.57 (1H, d, $J=13.7$), 3.91 (1H, d, $J=13.3$), 3.70 (2H, q, $J=8.6$), 3.45 (2H, s), 3.34-3.22 (3H, m), 3.16-3.07 (1H, m), 2.93-2.77 (3H, m), 2.54-2.48 (2H, m),
10 2.13 (3H, s), 2.13-2.06 (2H, m), 1.96-1.81 (2H, m), 1.78-1.73 (2H, m), 1.36-1.27 (2H, m). m/z 554, 555, 556.
